Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
about
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
description
clinical trial
@en
klinisch onderzoek
@nl
name
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@en
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@nl
type
label
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@en
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@nl
prefLabel
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@en
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@nl
P1476
Evaluation of Talazoparib, a P ...... enotyping Based Clinical Trial
@en
P3098
NCT03990896
P4844
P580
2019-07-31T00:00:00Z
P582
2022-07-31T00:00:00Z